造血干细胞移植受者诺卡菌感染:欧洲血液与骨髓移植学会感染病工作组多中心国际回顾性研究
该多中心国际回顾性研究纳入2000年至2018年间33国135个移植中心的81例造血干细胞移植后诺卡菌病,中位发生时间为移植后8个月,肺部受累86%、脑受累37%、播散性感染57%,1年全因死亡率40%。多因素分析显示基础疾病未完全缓解和既往细菌感染与1年全因死亡率升高相关。
要点
- 诺卡菌病多发生于移植后晚期,常表现为肺部病变伴频繁播散和脑受累。
- 脑受累患者中33%无神经系统症状,所有诺卡菌病移植受者均应行脑影像学检查。
- 总体死亡率高,1年全因死亡率为40%。
核心结论
- 诺卡菌病是造血干细胞移植后晚期感染,常表现为肺部病变伴频繁播散、脑感染和菌血症,总体死亡率高。
研究设计与样本
- 回顾性国际研究,纳入2000年1月1日至2018年12月31日33国135个移植中心的81例造血干细胞移植受者诺卡菌病发作。
主要发现
- 移植后中位8个月(IQR 4-18)发生诺卡菌病,肺部受累70/81(86%)、脑受累30/81(37%)、播散性感染46/81(57%)。
- 分子鉴定菌种中以Nocardia farcinica最常见(27%;12/44)。
- 1年全因死亡率为40%(32/81),末次随访(IQR 4-42.5个月)全因死亡率为52%(42/81)。
- 多因素分析中,基础疾病未完全缓解(HR 2.81;95%CI 1.32-5.95)和既往细菌感染(HR 3.42;95%CI 1.62-7.22)与1年全因死亡率升高相关。
关键数值与推荐
- 药敏率最高为利奈唑胺(45/45;100%)、阿米卡星(56/57;98%)、甲氧苄啶-磺胺甲噁唑(57/63;90%)和亚胺培南(49/57;86%)。
临床怎么用
- 造血干细胞移植受者出现诺卡菌病时,无论有无神经系统症状均应行脑影像学检查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nocardiosis is rare after hematopoietic cell transplantation (HCT). Little is known regarding its presentation, management, and outcome in this population. METHODS: This retrospective international study reviewed nocardiosis episodes in HCT recipients (1/1/2000-31/12/2018; 135 transplant centers; 33 countries) and described their clinical, microbiological, radiological, and outcome characteristics. RESULTS: We identified 81 nocardiosis episodes in 74 allo- and 7 auto-HCT recipients. Nocardiosis occurred a median of 8 (IQR: 4-18) months post-HCT. The most frequently involved organs were lungs (70/81; 86%) and brain (30/81; 37%); 29 (36%) patients were afebrile; 46/81 (57%) had disseminated infections. The most common lung imaging findings were consolidations (33/68; 49%) or nodules (32/68; 47%); brain imaging findings were multiple brain abscesses (19/30; 63%). Ten of 30 (33%) patients with brain involvement lacked neurological symptoms. Fourteen of 48 (29%) patients were bacteremic. Nocardia farcinica was the most common among molecularly identified species (27%; 12/44). Highest susceptibility rates were reported to linezolid (45/45; 100%), amikacin (56/57; 98%), trimethoprim-sulfamethoxazole (57/63; 90%), and imipenem (49/57; 86%). One-year and last follow-up (IQR: 4-42.5 months) all-cause mortality were 40% (32/81) and 52% (42/81), respectively. In the multivariable analysis, underlying disease not in complete remission (HR: 2.81; 95% CI: 1.32-5.95) and prior bacterial infection (HR: 3.42; 95% CI: 1.62-7.22) were associated with higher 1-year all-cause mortality. CONCLUSIONS: Nocardiosis is a late post-HCT infection usually manifesting as a pulmonary disease with frequent dissemination, brain infection, and bacteremia. Brain imaging should be performed in HCT recipients with nocardiosis regardless of neurological symptoms. Overall mortality is high.
引用
- Averbuch D, De Greef J, Duréault A, et al. Nocardia Infections in Hematopoietic Cell Transplant Recipients: A Multicenter International Retrospective Study of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation. Clin Infect Dis. 2022. PMID: 34596213. doi:10.1093/cid/ciab866
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。